관절통 주사제 시장 - 예측(2026-2031년)

Joint Pain Injections Market is expected to grow at a 7.37% CAGR, achieving USD 9.364 billion in 2031 from USD 6.111 billion in 2025.

The joint pain injections market is experiencing a significant uptrend, primarily driven by the rising global incidence of musculoskeletal conditions such as osteoarthritis and arthritis. These conditions profoundly impact patient mobility and quality of life, creating a substantial demand for effective pain management solutions. The growing elderly population worldwide is a key demographic factor amplifying this need. Joint pain injections, or intra-articular injections, represent a minimally invasive procedure where medication is administered directly into the joint to relieve pain and inflammation. Their appeal lies in offering faster recovery times and longer-lasting effects compared to systemic oral medications or surgical interventions, making them a cornerstone of modern orthopedic care and chronic pain management.

Primary Market Growth Drivers and Restraints

A major driver for market expansion is the global increase in risk factors for joint disease. The rising prevalence of obesity places excessive mechanical strain on joints, elevating the risk of dysfunction and degenerative conditions. Coupled with this, sedentary lifestyles can lead to weakened supporting musculature, further contributing to joint vulnerability. The demographic shift towards an older population is another fundamental driver, as age is a primary risk factor for the development of osteoarthritis.

A defining trend within the market is the rising adoption of regenerative therapies. While traditional injections like corticosteroids and hyaluronic acid provide symptomatic relief by reducing inflammation and supplementing joint fluid, regenerative options such as platelet-rich plasma (PRP) and stem cell therapies aim to promote tissue repair and long-term joint health. Growing clinical evidence supporting their efficacy, patient demand for alternatives to surgery, and technological advancements in cell therapy production are collectively propelling these sophisticated options into the mainstream.

However, the market's growth is tempered by certain restraints. The high cost of treatment, particularly for regenerative therapies and courses requiring multiple injections, can limit patient access. This challenge is often compounded by limited or variable insurance coverage, resulting in significant out-of-pocket expenses. Furthermore, a range of alternative treatments exists, including physical therapy, oral analgesics, NSAIDs, and assistive devices, which compete with injections, especially for managing mild to moderate joint pain.

Market Segmentation and Regional Outlook

The market is segmented by product and joint type. In terms of products, hyaluronic acid injections have secured a significant market share, valued for their ability to alleviate pain and improve mobility in osteoarthritic joints. Regarding joint type, the knee segment represents the largest market share, attributable to the high prevalence of knee osteoarthritis and the considerable stress the knee joint endures.

Geographically, North America holds a leading position in the market. This dominance is supported by a high prevalence of chronic joint diseases, a well-developed healthcare infrastructure, and a rapid rate of adoption for innovative therapies. Europe also represents a mature market, characterized by a strong pharmaceutical sector and continuous medical advancements.

The Asia-Pacific region is anticipated to witness the most rapid growth. This is fueled by a large and aging population, increasing healthcare awareness, expanding hospital infrastructure, and growing investments in pharmaceutical research and development. Markets in South America and the Middle East & Africa are developing, with growth concentrated in more affluent, urban areas. In these regions, expansion is driven by rising healthcare investment, growing medical tourism, and increasing patient awareness, though access remains limited in rural areas due to infrastructure and cost constraints.

Competitive Landscape and Strategic Developments

The market is competitively served by a mix of multinational pharmaceutical and biotechnology companies. Key players are actively engaged in strategic initiatives to strengthen their market position. These strategies include robust research and development programs focused on novel therapies, strategic collaborations and partnerships to enhance product portfolios and distribution, and geographic expansion efforts to commercialize innovative products in new markets. The competitive dynamics are shaped by a continuous focus on innovation, particularly in the realm of regenerative medicine and advanced therapeutic solutions.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Joint Pain Injections Market Segmentation:

• By Type
• Corticosteroid
• Hyaluronic Acid Injections
• Platelet Rich Plasma (PRP) Injections
• Others
• By Joint Type
• Knee Joint
• Hands & Wrist Joint
• Hip Joint
• Others
• By End-User
• Hospitals
• Clinics
• Others
• By Geography
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Italy
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. JOINT PAIN INJECTIONS MARKET BY TYPE

• 5.1. Introduction
• 5.2. Corticosteroid
• 5.3. Hyaluronic Acid Injections
• 5.4. Platelet Rich Plasma (PRP) Injections
• 5.5. Others

6. JOINT PAIN INJECTIONS MARKET BY JOINT TYPE

• 6.1. Introduction
• 6.2. Knee Joint
• 6.3. Hands & Wrist Joint
• 6.4. Hip Joint
• 6.5. Others

7. JOINT PAIN INJECTIONS MARKET BY END-USER

• 7.1. Introduction
• 7.2. Hospitals
• 7.3. Clinics
• 7.4. Others

8. JOINT PAIN INJECTIONS MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Italy
  • 8.4.6. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Israel
  • 8.5.4. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Sanofi
• 10.2. Seikagaku Corporation
• 10.3. Bioventus
• 10.4. Anika Therapeutics, Inc.
• 10.5. Pacira BioSciences, Inc.
• 10.6. Dr. Reddy's Laboratories Ltd
• 10.7. Zimmer Biomet
• 10.8. Pfizer Inc
• 10.9. Teva Pharmaceutical Industries Ltd.
• 10.10. Ferring Pharmaceuticals
• 10.11. Eli Lilly And Company

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations